rowth hormone (GH), prolactin (PRL), and placental lactogen (PL) are the most potent growth factors that have been identified for pancreatic ␤-cells to date. In addition, these hormones stimulate insulin production, partially via direct transcriptional activation of the insulin promoter. These effects are mediated through the GH receptor (GHR) and the PRL receptor (PRLR), which are both expressed in rat islets as well as in various insulinoma cell lines (1). The GH and PRL receptors are transmembrane proteins belonging to the cytokine receptor superfamily. These receptors are characterized by the ability to activate signal transducers and activators of transcription (STAT) proteins, which are latent transcription factors that become activated by phosphorylation of a single tyrosine residue by receptor-associated Janus kinases (JAKs). The phosphorylated STAT proteins dimerize and translocate to the nucleus, where they bind specific DNA elements and activate transcription (2). Recently, we have demonstrated that GH and PRL activate DNA binding of STAT1, 3, and 5 in rat insulinoma cells (3, 4) . In correlation with these results, Sorenson and coworkers (5) have reported GH-and PRLinduced nuclear translocation of STAT5 in INS-1 cells and in cultured rat islets. Furthermore, we have identified STAT5 binding elements in the rat insulin 1 promoter as well as in one of the PRLR promoters required for transcriptional activation by human GH (hGH), which binds GH as well as PRL receptors in rodents (3,4). Apart from the JAK/STAT pathway, several other signaling pathways-such as the ras/raf/MAPK (mitogen-activated protein kinase), phosphatidylinositol 3-kinase, and protein kinase C cascades-are activated in various cell types in response to GH and PRL (2). The signaling pathways involved in GH/PRL-induced ␤-cell mitogenesis have not been identified. The aim of the present study was therefore to determine the role of STAT5 in GH-and PRL-stimulated proliferation in the INS-1 cells.
therefore to determine the role of STAT5 in GH-and PRL-stimulated proliferation in the INS-1 cells.
The Tet-On gene expression system was employed to generate stably transfected INS-1 cells expressing, in an inducible manner, the dominant-negative STAT5 mutant, STAT5a⌬749, which lacks the COOH-terminal transactivation domain. The INS-1-derived clone INS-r3, which carries the reverse tetracycline/doxycycline-dependent transactivator (6) (provided by Dr. Wollheim, Switzerland), was transfected with the pTRE-vector containing the cDNA encoding STAT5a⌬749 under the control of the tetracycline operator. Control transfection was preformed with the empty pTREvector, and stable clones were generated that carried either the empty pTRE vector or the pTRE-STAT5a⌬749 construct. Western blot analysis demonstrated that the pTRESTAT5a⌬749-transfected cells expressed the truncated STAT5 mutant dose-dependently in response to doxycycline treatment, whereas doxycycline had no effect on STAT5 protein expression in control cells. Gel retardation analysis showed that in pTRE-STAT5a⌬749-transfected cells, but not in control cells, doxycycline treatment dose-dependently increased hGH-induced STAT5 DNA binding likely to represent binding of STAT5a⌬749. Dual luciferase reporter assay was used to address whether overexpression of STAT5a⌬749 would suppress signaling via endogenously expressed STAT5. hGH-induced transcriptional activation of the STAT5-responsive PRLR promoter was found to be inhibited by doxycycline in a dose-dependent manner only in pTRESTAT5a⌬749-transfected cells. The effect of STAT5a⌬749 overexpression on the endogenous PRLR mRNA level was investigated by quantitative reverse transcriptase-polymerase chain reaction. The level of PRLR mRNA induction by hGH in pTRE-STAT5a⌬749-transfected cells and in control cells was similar to the induction level previously demonstrated in the parental INS-1 cells. Overexpression of dominant-negative STAT5 by doxycycline treatment was found to suppress the hGH-induced PRLR mRNA expression in a dose-dependent manner in pTRE-STAT5a⌬749-transfected cells. In contrast, doxycycline treatment had no effect on hGH-induced PRLR mRNA expression in control cells. These data confirm our previous finding of a primary role of STAT5 in the regulation of the PRLR gene (4) .
To determine the influence of dominant-negative STAT5 activity on cell proliferation, [ H]thymidine incorporation by dominant-negative STAT5 expression was due to an effect on S-phase entry, the cell cycle profiles were examined by fluorescence-activated cell sorter analysis using propidium iodide to determine DNA content and fluorescein isothiocyanate-conjugated anti-BrdU antibody to detect BrdU incorporation. Stimulation with hGH was found to increase the percentage of cells in S-phase, and this increase was totally blocked by doxycycline in pTRE-STAT5a⌬749-transfected cells but not in control cells. These results indicate that GH-and PRL-induced ␤-cell proliferation is dependent on STAT5 signaling.
To determine the kinetics of STAT5 activation in INS-1 cells as well as in cultured newborn rat islets, gel retardation analysis was performed. After 15 min, STAT5 binding activity was strongly induced by hGH in INS-1 cells and remained elevated for the duration of hGH stimulation (up to 48 h). A similar pattern was observed in cultured newborn rat islets, although the level of STAT5 activation was somewhat reduced after prolonged hGH treatment. In contrast to the long-term induction of STAT5 in cultured newborn rat islets and in INS-1 cells, we have previously reported that induction of STAT5 in RIN-5AH cells is only transient (3) . Because the effect of hGH on proliferation and gene expression is relatively small in the RIN-5AH cells, the potency of hGH action in insulin-producing cells might be correlated to the duration of STAT5 activation.
In conclusion, STAT5 might play an important role in GH and PRL signaling in pancreatic ␤-cells, mediating the stimulatory effects of these hormones on ␤-cell gene expression and proliferation.
